Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
Holding STTK?
Track your performance easily
STTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.33 - $11.76
Previous Close$3.69
Volume172.01K
Average Volume (3M)384.38K
Market Cap
$176.11M
Enterprise Value$73.74M
Total Cash (Recent Filing)$105.34M
Total Debt (Recent Filing)$2.97M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 05, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding47,727,269
10 Day Avg. Volume131,849
30 Day Avg. Volume384,385
Standard Deviation0.47
R-Squared0.03
Alpha-0.00237
Financial Highlights & Ratios
Price to Book (P/B)1.62
Price to Sales (P/S)42.70
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.88
Enterprise Value/Gross Profit44.50
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$10.67Price Target Upside184.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Shattuck Labs News
Bulls Say, Bears Say
Bulls Say
Clinical DataUpdated Phase 1b data for SL-172154 in combination with azacitidine in high-risk myelodysplastic syndromes and TP53-mutant acute myeloid leukemia showed improved and stable complete remission and overall response rates above most historical data.
FinancialsThe company ended the quarter with $117.2 million in cash, which management believes provides runway for all ongoing operations into 2026, beyond results from its Phase 1 clinical trials of SL-172154.
Regulatory EnvironmentWith the FDA showing growing comfort with minimal residual disease analyses, there is a possibility that this effect, if replicated in randomized cohorts, could ultimately form the basis of an accelerated approval.
Bears Say
Adverse EventsGrade ≥3 AEs increased to more than 30% in each cohort, the majority being IRRs.
Clinical StudiesDespite promising starts, the past year in the CD47 landscape has been marked by languishing clinical studies and disappointing safety results, casting a challenging perception over the field at large.
Investor ConfidenceThe stock remains depressed following continued low confidence among investors on CD47.
---
Ownership Overview
26.24% Insiders
19.54% Mutual Funds
41.03% Other Institutional Investors
13.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $1.33 and its highest was $11.76 in the past 12 months.
What is Shattuck Labs’s market cap?
Currently, no data Available
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Aug 01, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.414 by -$0.006.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -$0.44.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 47,727,270 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.414. Following the earnings report the stock price went down -3.183%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
---
Shattuck Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (184.53% Upside)
$10.67 (184.53% Upside)
Blogger Sentiment
Neutral
STTK Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $82.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.00%
12-Months-Change
Fundamentals
Return on Equity
-68.48%
Trailing 12-Months
Asset Growth
-17.17%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
---
STTK Earnings Call
Q3 2023
0:00 / 0:00
---
STTK Stock 12 Month Forecast
Average Price Target
$10.67
▲(184.53% Upside)
Technical Analysis
Best Analysts Covering STTK
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+37.86%
reiterated a buy rating 24 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +37.86% per trade.
---